CFO interim
Keros Therapeutics, Inc. names Annita Tanini interim CFO
Keros Therapeutics, Inc. reported in a Form 8-K filed July 22, 2026 that Annita Tanini was named interim principal financial officer and principal accounting officer, effective August 4, 2026.
In the filing's words
On July 17, 2026, Keith Regnante resigned from his role as Chief Financial Officer of Keros Therapeutics, Inc. (the “Company”), effective August 3, 2026 (the “Separation Date”), to pursue other opportunities.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Keros Therapeutics, Inc. (KROS) |
|---|---|
| Event | Interim |
| Incoming | Annita Tanini |
| Outgoing | Keith Regnante |
| Title in the filing | interim principal financial officer and principal accounting officer |
| Effective | August 4, 2026 |
| 8-K filed | July 22, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Corporate Controller and Vice President, Finance, Keros Therapeutics, Inc. |
| SEC CIK | 0001664710 |
Keros Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed July 22, 2026. The filing's own words are quoted above.
Other records naming Keith Regnante
1The outgoing officer on this record, matched by name. Career line.
2026-03-04 · 10-K signature
Keith Regnante signed Keros Therapeutics, Inc.'s annual report as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
Same industry, July 2026
7Other moves filed that month at companies the roster files under SIC “Pharmaceutical Preparations”.
3 months ago· 2026-07-31AppointmentGCAN
The Greater Cannabis Company, Inc. appoints Michelle Cervantes Vivanco as CFO
3 months ago· 2026-07-28TransitionVYNE
Yarrow Bioscience, Inc. CFO transition: Tyler Zeronda to succeed Mutya Harsch
3 months ago· 2026-07-20AppointmentPMHS
Polomar Health Services, Inc. appoints Douglas Beck as CFO
4 months ago· 2026-07-13AppointmentMBX
MBX Biosciences, Inc. appoints John Smither as CFO
4 months ago· 2026-07-08TransitionOVID
Ovid Therapeutics Inc. CFO transition: Charles Carter to succeed Jeffrey Rona
4 months ago· 2026-07-06TransitionLGVN
Longeveron Inc. CFO transition: Marie Washburn to succeed Lisa Locklear
4 months ago· 2026-07-06AppointmentOGEN
Oragenics, Inc. appoints John Spencer as CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Annita Tanini? Send a correction with the primary source.